Size: | Price | Quantity | |
---|---|---|---|
5 mg | $50.00 | ||
25 mg | $130.00 |
Quizartinib (950769-58-1) is a potent and selective inhibitor of FLT3 (Kd = 1.6nM, IC50 = 0.56 nM MV4-11 cells).1 It is in clinical trials for treatment of Acute Myelogenous Leukemia (AML).2,3 Quizartinib priming resulted in prevention of myelosuppression in mice treated with 5-FU and Gemcitabine.4 Quizartinib showed significant reversal of ABCG2-mediated multidrug resistance (@ 3 µM) via antagonism of drug efflux function.5,6
References/Citations:
1) Chao et al. (2009) Identification of N-(5-tert-butyl-isoxazol-3-yl)-N’-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor; J. Med. Chem. 52 7808
2) Zarrinkar et al. (2009); AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia(AML); Blood 114 2984
3) Fathi and Chen (2017); The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia; Eur. J .Haematol. 98 330
4) Taylor and Langdon (2017); Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy; Mol. Cell Oncol. 4 e1378156
5) Li et al. (2017); Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and In vivo studies; Oncotarget 8 93785
6) Bhullar et al. (2013) The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug reactions; PLoS One 8 e71266
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Quizartinib (950769-58-1) is a potent and selective inhibitor of FLT3 (Kd = 1.6nM, IC50 = 0.56 nM MV4-11 cells).1 It is in clinical trials for treatment of Acute Myelogenous Leukemia (AML).2,3 Quizartinib priming resulted in prevention of myelosuppression in mice treated with 5-FU and Gemcitabine.4 Quizartinib showed significant reversal of ABCG2-mediated multidrug resistance (@ 3 µM) via antagonism of drug efflux function.5,6
References/Citations:
1) Chao et al. (2009) Identification of N-(5-tert-butyl-isoxazol-3-yl)-N’-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor; J. Med. Chem. 52 7808
2) Zarrinkar et al. (2009); AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia(AML); Blood 114 2984
3) Fathi and Chen (2017); The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia; Eur. J .Haematol. 98 330
4) Taylor and Langdon (2017); Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy; Mol. Cell Oncol. 4 e1378156
5) Li et al. (2017); Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and In vivo studies; Oncotarget 8 93785
6) Bhullar et al. (2013) The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug reactions; PLoS One 8 e71266
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.